Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278283 | 0.85 | USP8 (0.35) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL2273613 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL13962776 | 0.76 | CES2 (0.37) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL2270437 | 0.65 | RAB9A (0.38) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL14619317 | 0.65 | KAT6A (0.32) | SMN1; SMN2MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL19925907 | 0.63 | CES2 (0.47) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL29875006 | 0.63 | CES2 (0.47) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL4753735 | 0.63 | NPC1 (0.32) | SMN1; SMN2MEN1KMT2AALDH1A1CES2 | |
| SCHEMBL31468409 | 0.60 | CES2 (0.50) | SMN1; SMN2MEN1GAAKMT2ALMNA | |
| SCHEMBL8691227 | 0.60 | CES2 (0.50) | SMN1; SMN2MEN1GAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994337-B2 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090118272-A1 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-7473784-B2 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070185175-A1 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118272-A1 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | GRK2, MAPK9, MAPK1 | SMN1; SMN2 3443/4885MEN1 3704/4885GAA 1925/4885 |
| US-20070185175-A1 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | GRK2, MAPK1, GRK4 | SMN1; SMN2 3578/4885MEN1 3532/4885GAA 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.